The DOI matches its Crossref record; 25 of the 41 references it cites were found in a registry or an index, and 15 are not checked yet; 8 of the 37 sources its claims cite were checked for support.
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Open accessAbstract
Background: Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk of cardiovascular (CV) events in those with high CV risk. GLP-1RAs might also have kidney-protective effects. We report the design and baseline data for FLOW (NCT03819153), a trial investigating the effects of semaglutide, a once-weekly (OW) GLP-1RA, on kidney outcomes in participants with CKD and T2D. Methods: FLOW is a randomised, double-blind, parallel-group, multinational, phase 3b trial. Participants with T2D, estimated glomerular filtration rate (eGFR) ≥50‒≤75 ml/min/1.73 m2 and urine albumin:creatinine ratio (UACR) >300‒<5000 mg/g or eGFR ≥25‒<50 ml/min/1.73 m2 and UACR >100‒<5000 mg/g were randomised 1:1 to OW semaglutide 1.0 mg or matched placebo, with renin–angiotensin–aldosterone system blockade (unless not tolerated/contraindicated). The composite primary endpoint is time to first kidney failure (persistent eGFR <15 ml/min/1.73 m2 or initiation of chronic kidney replacement therapy), persistent ≥50% reduction in eGFR or death from kidney or CV causes. Results: Enrolled participants (N = 3534) had a baseline mean age of 66.6 years [standard deviation (SD) 9.0], haemoglobin A1c of 7.8% (SD 1.3), diabetes duration of 17.4 years (SD 9.3), eGFR of 47.0 ml/min/1.73 m2 (SD 15.2) and median UACR of 568 mg/g (range 2‒11 852). According to Kidney Disease: Improving Global Outcomes guidelines categorisation, 68.2% were at very high risk for CKD progression. Conclusion: FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to be completed in late 2024.
Verified 2026-10-05 · 15 references not checked yet
Overview
CoChat Summary
TL;DR
FLOW is a randomised, double-blind, phase 3b kidney outcomes trial testing once-weekly semaglutide 1.0 mg versus placebo in 3534 adults with type 2 diabetes and chronic kidney disease. This report describes the rationale, design, and baseline characteristics; efficacy results are not yet available.
Key findings
- FLOW enrolled 3534 participants across 418 sites in 28 countries; baseline mean age was 66.6 years (SD 9.0), 69.7% were male, and 65.7% were white.
- Baseline kidney burden was substantial: mean eGFR 47.0 ml/min/1.73 m² (SD 15.2), median UACR 568 mg/g (range 2–11 852), 68.4% had macroalbuminuria, and 68.2% were classified as very high risk for CKD progression by KDIGO criteria.
- Baseline diabetes and cardiovascular burden included mean HbA1c 7.8% (SD 1.3), mean diabetes duration 17.4 years (SD 9.3), BMI 32.0 kg/m² (SD 6.3), 52.0% with previous cardiovascular disease, and 19.1% with previous heart failure.
- At baseline, 95.3% were receiving RAAS inhibitors, 15.5% SGLT2is, 61.5% insulin, and 51.6% metformin; the trial was powered to detect a 20% relative risk reduction (HR 0.8) for the primary composite endpoint, requiring 854 events.
Methods
- Randomised, double-blind, parallel-group, multinational phase 3b trial; adults with type 2 diabetes and CKD were eligible if they had eGFR ≥50–≤75 ml/min/1.73 m² and UACR >300–<5000 mg/g, or eGFR ≥25–<50 ml/min/1.73 m² and UACR >100–<5000 mg/g, on stable maximum labelled or tolerated RAAS blockade unless contraindicated or not tolerated.
- Participants were randomised 1:1 to once-weekly subcutaneous semaglutide 1.0 mg or matched placebo, stratified by SGLT2i use at baseline; the primary composite endpoint was time to first kidney failure, persistent ≥50% reduction in eGFR, or death from kidney or cardiovascular causes.
- Baseline data are reported descriptively from 3534 randomised participants using central laboratory eGFR and UACR assessments; the event-driven trial uses a group sequential design, intention-to-treat estimand, and stratified Cox proportional hazards model.
Limitations
- The paper states that eligibility could be based on historical laboratory values, but baseline data came from central laboratory assessments, resulting in a small number of participants not fulfilling all inclusion criteria at that specific visit.
- The paper states that the mechanism of kidney protection with GLP-1RAs is not fully elucidated, and that prior kidney data from cardiovascular outcomes trials are hypothesis generating because of low CKD prevalence and secondary endpoints.
- Evident from the text: this report provides rationale, design, and baseline characteristics only; no FLOW efficacy or safety outcome results are reported, so treatment effects on kidney outcomes remain unknown.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 1: Results of exploratory kidney analyses from GLP-1RA CV outcomes trials. *P < .05. †Defined as doubling of serum creatinine in LEADER, SUSTAIN 6 and ELIXA and sustained eGFR decline of ≥30% in REWIND. Direct comparisons not possible due to differing study designs. Secondary kidney composite endpoints were new-onset persistent macroalbuminuria/very high albuminuria, persistent doubling of the serum creatinine or end-stage kidney disease in LEADER; first occurrence of new macroalbuminuria/very high albuminuria (UACR >33.9 mg/mmol), a sustained decline in eGFR of ≥30% or chronic KRT in REWIND; new or worsening nephropathy (defined as persistent macroalbuminuria/very high albuminuria, persistent doubling of serum creatinine and a creatinine clearance of <45 ml/min/1.73 m2 or the need for continuous KRT) in SUSTAIN 6; a 40% decline in eGFR, KRT, kidney death or incident macroalbuminuria/very high albuminuria in EXSCEL; and incident macroalbuminuria (UACR >33.9 mg/mmol) plus an increase in UACR of ≥30% from baseline, sustained decrease in eGFR of ≥40% for ≥30 days, renal replacement therapy for ≥90 days and sustained eGFR <15 ml/min/1.73 m2 for ≥30 days in AMPLITUDE-O [6, 7, 10, 13, 38, 43]. exenatide ER, exenatide extended release; KRT, kidney replacement therapy; NR, not reported.](https://figures.cochat.ai/paper-figures/b2fee42ad49f40f2932559a7a8cf87fb/the-rationale-design-and-baseline-data-of-flow-a-kidney-outcomes-trial-with-once-figure-1.jpg)


![Figure 4: KDIGO risk categories among FLOW participants. Data are n (%) for each category. To facilitate recruitment to the FLOW trial and increase generalisability of the outcomes by reflecting typical clinical practice, eligibility in terms of laboratory results could be based on historical values. Adapted from the KDIGO Diabetes Work Group, 2020 [3].](https://figures.cochat.ai/paper-figures/74d173ee74c241588481e8180bd957d7/the-rationale-design-and-baseline-data-of-flow-a-kidney-outcomes-trial-with-once-figure-4.jpg)
Verification
Claims the paper makes
4 Valid · 1 Not valid · 17 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, these benefits were driven by a lower risk of persistent macroalbuminuria [6,10,13].”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > INTRODUCTION
What the sources say
- Not checked yetcites [6] Gerstein, 2019, Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, Lancet source
- Partly supportedcites [10] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion of our copy states that 'Semaglutide-treated patients had a lower risk of new or worsening nephropathy, according to differences in macroalbuminuria', and the Table 2 footnote (Other Outcomes) defines new or worsening nephropathy as including 'persistent macroalbuminuria', with the composite reduced (HR 0.64; 95% CI, 0.46–0.88; P = 0.005; Results/Microvascular Outcomes). So the driving-component point is supported for semaglutide. However, this source is a single 104-week semaglutide RCT in type 2 diabetes with elevated cardiovascular risk, not a meta-analysis of GLP-1 receptor agonists; the pooled, class-level framing ('kidney benefits of GLP-1 receptor agonists in these meta-analyses') is not what this paper reports. (LLM, conf=0.75)
- Supportedcites [13] Mann, 2017, Liraglutide and renal outcomes in type 2 diabetes, N Engl J Med source
Our copy states the attributed point twice: the RESULTS (p. 1) report the composite renal outcome favoured liraglutide (268 vs. 337 patients; HR 0.78) and say 'This result was driven primarily by the new onset of persistent macroalbuminuria' (161 vs. 215; HR 0.74, P = 0.004), while the Discussion (p. 7) repeats that the result 'was driven mainly by a lower incidence of macroalbuminuria', with non-significant effects on doubling of serum creatinine and end-stage renal disease (Table 1, p. 4). The cited work is a prespecified analysis of the single LEADER trial rather than a meta-analysis, and its finding concerns liraglutide specifically; the 'these meta-analyses' framing and the class-level wording belong to the citing authors' own synthesis, for which this citation supplies the liraglutide component it is offered for. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > INTRODUCTION
What the sources say
- Not checked yetcites [6] Gerstein, 2019, Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, Lancet source
- Supportedcites [7] Gerstein, 2021, Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes, N Engl J Med source
AMPLITUDE-O's Conclusions (p. 1) state that in participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower with weekly efpeglenatide (4 or 6 mg) than with placebo; the Discussion (p. 7) quantifies this as a 27% lower risk of incident MACE, and Trial Design (p. 2) defines the high-risk/established-CVD population. The Background (p. 1) additionally supports the class-level framing ('Four GLP-1 receptor agonists ... structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes'). The other named agents in the citing sentence's citation cluster are carried by the sibling references, not this one, so nothing attributed to this source is unsupported. (LLM, conf=0.90)
- Partly supportedcites [8] Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet sourceExperimental — accuracy not yet measured
Our copy of Harmony Outcomes supports three of the five drugs listed: the Abstract and Discussion report that once-weekly albiglutide reduced the MACE composite (CV death, non-fatal MI, non-fatal stroke) by 22% (HR 0·78, 95% CI 0·68-0·90) in patients with type 2 diabetes and established cardiovascular disease, and 'Research in context' reports the LEADER MACE reduction with liraglutide (0·87) and the SUSTAIN-6 result with once-weekly semaglutide (0·74). However, dulaglutide appears in our copy only as one of the PubMed search terms, with no trial result reported, and efpeglenatide is not mentioned at all (both the REWIND and AMPLITUDE-O trials postdate this 2018 paper), so those two members of the claim's drug list are not supported here. The 'or at high risk of CVD' qualifier is also broader than this trial's population, which enrolled patients with established cardiovascular disease only. (LLM, conf=0.80)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“some reduce the risk of cardiovascular (CV) events in those with high CV risk”
- Also stated in: § INTRODUCTION · plain
“Some GLP-1RAs [albiglutide, efpeglenatide, dulaglutide, liraglutide and once-weekly (OW) semaglutide] reduce the risk of major adverse CV events (MACE) in people with T2D with established CVD or at high risk of CVD [6][7][8][9][10].”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > Abstract
What the sources say
- Not checked yetcites [6] Gerstein, 2019, Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial, Lancet source
- Supportedcites [7] Gerstein, 2021, Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes, N Engl J Med source
The BACKGROUND (p. 1) states that four GLP-1 receptor agonists structurally similar to human GLP-1 'have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes,' and the ABSTRACT (p. 1-2) says the effects of GLP-1 receptor agonists 'on cardiovascular and renal outcomes in persons with cardiovascular disease have been reported' (citing Kristensen et al. 2019, ref. 10). The Discussion (p. 7) reiterates these 'previously reported salutary effects' in a population of high-risk patients. This is a broad background statement our copy clearly endorses, so the paraphrase ('some reduce the risk of CV events in those with high CV risk') is supported, including the 'some' qualifier and the high-risk population. (LLM, conf=0.85)
- Supportedcites [8] Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet source
The Introduction (p. 1) states that 'not all tested GLP-1 receptor agonists have been shown to reduce cardiovascular events' and that 'Liraglutide and semaglutide... reduced cardiovascular events, whereas no benefit was associated with the exendin-4 based drugs lixisenatide and exenatide' — i.e. some, not all. The Research in context panel and the trial summary place these effects in patients with type 2 diabetes with established cardiovascular disease or risk factors (the high-CV-risk population), and the concluding summary states 'these findings provide more evidence that certain GLP-1-receptor agonists can improve cardiovascular outcomes in patients with type 2 diabetes.' Both the 'some' qualifier and the high-risk population are therefore carried by our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § INTRODUCTION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median UACR of 568 mg/g (range 2-11 852)”
- Also stated in: § RESULT S · plain
“the median UACR was 568 mg/g (range 2-11 852)”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > Abstract
plainn = 3,534- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULT S · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“According to Kidney Disease: Improving Global Outcomes guidelines categorisation, 68.2% were at very high risk for CKD progression.”
- Also stated in: § RESULT S · plain
“According to KDIGO categories [3], the majority of participants (68.2%) were classified as very high risk for CKD progression”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > Abstract
plainn = 3,534- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § RESULT S · plain
25 more claims
Create a free account to see all 79 claims and to verify the 29 references still open.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initially approved for T2D management, GLP-1 RAs have also demonstrated cardiovascular and renal benefits [5–7].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other outcomes were prespecified as exploratory (see the FLOW protocol in ref. 8).”
From Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This trial was event driven and designed to provide 90% power to detect a 20% relative risk reduction for semaglutide versus placebo for the primary outcome8.”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The FLOW trial8 recently reported that in participants with T2D and CKD, semaglutide 1.0 mg once weekly reduced the risk of major kidney disease events by 24% and blunted eGFR decline by 1.16 ml min−1/1.73 m2/year4.”
From Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > Population
“haemoglobin A 1c (HbA 1c ) ≤10% (<86 mmol/mol)”
§ The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease > Population
“HbA 1c ≤10% (≤86 mmol/mol)”
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“…2045 [1], there is a clear need for additional treatment options to help mitigate the residual risk in those individuals with concomitant CKD. Secondary analyses, primarily of CVOTs, suggest a potential kidney-protective effect of GLP-1RAs in people with T2D and at risk of CVD [6, 9–12 , 17– 28].”
BackgroundSelf-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Despite the availability of established and newer pharma-cotherapies to delay CKD progression in people with T2D, the risk of progression and the associated morbidity and mortality remains substantial [14, 15].”
BackgroundSelf-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 4×
“Despite the availability of established and newer pharmacotherapies to delay CKD progression in people with T2D, the risk of progression and the associated morbidity and mortality remains substantial [14, 15].”
BackgroundInfluentialSelf-citationNew creatinine- and cystatin C-based equations to estimate GFR without race
Inker, L. A., Eneanya, N. D., Coresh, J., Tighiouart, H., Wang, D., Sang, Y., Crews, D. C., Doria, A., Estrella, M. M., Froissart, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102953 · Cited by 4,695 · cited 1×
“Since the recruitment of FLOW trial participants, a new CKD-EPI formula without race as a factor has been recommended; a pre-specified supplementary analysis has now been added to evaluate the impact of the updated formula on the results [16].”
BackgroundSelf-citationHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Self-citationKDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citation
Research works printed but not linked: 1
- International Diabetes Federation, Diabetes Atlas
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Self-citationNdumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
“148 In the FIDELITY (Finere-none in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis) pooled analysis, among patients with T2D and CKD on maximally tolerated ACEI/ARB use, fi-nerenone led to reduced risk of kidney disease progression and CVD…”
MethodSelf-citationNeuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Metadata
- Authors
- Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., Mersebach, H., Perkovic, V., Tuttle, K., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk (Denmark) (DK)
- University of Chicago (US)
- Novo Nordisk A/S , Søborg , Denmark
- Stanford Medicine (US)
- Outpatients Clinic, KfH Kidney Center , München , Germany
- UNSW Sydney (AU)
- University of Washington (US)
- AdventHealth Orlando (US)
- Corresponding author
- Rossing, Peter
- ORCID
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-18
- Volume
- 38
- Issue
- 9
- Pages
- 2041-2051
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC10469096
- OpenAlex
- W4317213523
- Cited by
- 242
- References
- 41
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 107 · 2023: 46
- FWCI
- 46.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, type 2 diabetes, chronic kidney disease, renal failure, GLP-1 receptor agonists, FLOW trial, estimated glomerular filtration rate, albuminuria, renin-angiotensin-aldosterone system blockade, renal outcomes, trial design, baseline characteristics, cardiovascular outcomes
- MeSH terms
- Semaglutide, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Kidney, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. https://app.cochat.ai/papers/10.1093/ndt/gfad009
- The paper
- Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., Mersebach, H., Perkovic, V., Tuttle, K., & Pratley, R. (2023). The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.